Literature DB >> 20808304

Psoriasis: Is ustekinumab superior to etanercept for psoriasis?

Annegret Kuhn1, Thomas A Luger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20808304     DOI： 10.1038/nrrheum.2010.134

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Psoriasis.

Authors:  Michael P Schön; W-Henning Boehncke
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

2.  Ustekinumab poised to enter the psoriasis market.

Authors:  Charlie Schmidt
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

3.  Trial watch: novel biologic for psoriasis shows superiority over current best-seller.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2008-11       Impact factor: 84.694

4.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Authors:  Christopher E M Griffiths; Bruce E Strober; Peter van de Kerkhof; Vincent Ho; Roseanne Fidelus-Gort; Newman Yeilding; Cynthia Guzzo; Yichuan Xia; Bei Zhou; Shu Li; Lisa T Dooley; Neil H Goldstein; Alan Menter
Journal:  N Engl J Med       Date:  2010-01-14       Impact factor: 91.245

5.  Understanding the IL-23-IL-17 immune pathway.

Authors:  Brent S McKenzie; Robert A Kastelein; Daniel J Cua
Journal:  Trends Immunol       Date:  2005-11-14       Impact factor: 16.687

6.  TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.

Authors:  Alice B Gottlieb; Francesca Chamian; Salman Masud; Irma Cardinale; Maria Veronica Abello; Michelle A Lowes; Fei Chen; Melissa Magliocco; James G Krueger
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

7.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Authors:  Alice Gottlieb; Alan Menter; Alan Mendelsohn; Yaung-Kaung Shen; Shu Li; Cynthia Guzzo; Scott Fretzin; Rod Kunynetz; Arthur Kavanaugh
Journal:  Lancet       Date:  2009-02-11       Impact factor: 79.321

8.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

9.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Authors:  Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Shu Li; Lisa T Dooley; Kenneth B Gordon
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

10.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307
  10 in total
  1 in total

Review 1.  Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.

Authors:  Chao-Yang Lai; Yu-Wen Su; Kuo-I Lin; Li-Chung Hsu; Tsung-Hsien Chuang
Journal:  J Immunol Res       Date:  2017-08-13       Impact factor: 4.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.